Siglec‐F antibody administration to mice selectively reduces blood and tissue eosinophils

Abstract

Background: Sialic acid‐binding immunoglobulin‐like lectins (Siglecs) are a family of receptors that bind sialic acid and mostly contain immunoreceptor tyrosine‐based inhibitory motifs, suggesting that these molecules possess inhibitory functions. We have recently identified Siglec‐8 as an eosinophil‐prominent Siglec, and cross‐linking of Siglec‐8 on human eosinophils induces apoptosis. In this article, we address the in vivo consequences of Siglec engagement. We and others have identified mouse Siglec‐F as the closest functional paralog of human Siglec‐8, based on shared ligand‐binding and expression pattern. We therefore hypothesized that Siglec‐F engagement would affect levels and viability of eosinophils in vivo. Methods: Wild type and hypereosinophilic mice were administered Siglec‐F antibody and levels of eosinophils in peripheral blood and tissue were measured. Eosinophil apoptosis (in vivo and in vitro) was determined by binding of Annexin‐V. Results: Studies in IL‐5 transgenic mice, displaying hypereosinophilia, show that administration of a single dose of Siglec‐F antibody results in rapid reductions in quantum of eosinophils in the blood. This decrease was accompanied by reductions in tissue eosinophils. Quantum of eosinophils in blood was decreased using two separate antibodies, as well as in other mouse models (wild type mice and in a mouse model of chronic eosinophilic leukemia). Mechanistic studies demonstrated that Siglec‐F antibody administration induced apoptosis of eosinophils in vivo and in vitro. Conclusion: These data demonstrate that activation of innate immune receptors, like Siglec‐F, can significantly reduce mouse eosinophil viability. As such, targeting Siglec‐8/F may be a therapeutic approach for eosinophilic disorders.